CT News and Research RSS Feed - CT News and Research

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC). [More]
Study reveals new information about role of abdominal fat in teens with CAH

Study reveals new information about role of abdominal fat in teens with CAH

Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD). [More]
Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Elekta has signed a contract with one of Korea's most advanced hospitals, Samsung Medical Center in Seoul, to deliver the first Leksell Gamma Knife Icon to Asia. [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
Phase II clinical trial of Linsitinib launched in patients with advanced Ewing sarcoma

Phase II clinical trial of Linsitinib launched in patients with advanced Ewing sarcoma

EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes. [More]
Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16. [More]
Daily sugar-sweetened beverage habit may increase NAFLD risk

Daily sugar-sweetened beverage habit may increase NAFLD risk

A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers from the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HRNCA) at Tufts University report today in the Journal of Hepatology. [More]
Study can help spur beneficial lifestyle changes in patients to reduce Alzheimer's risk

Study can help spur beneficial lifestyle changes in patients to reduce Alzheimer's risk

Armed with new knowledge about how neurodegenerative diseases alter brain structures, increasing numbers of neurologists, psychiatrists and other clinicians are adopting quantitative brain imaging as a tool to measure and help manage cognitive declines in patients. These imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease. [More]
Frisbie Memorial Hospital now uses low-dose CT scanning for screening colorectal cancer

Frisbie Memorial Hospital now uses low-dose CT scanning for screening colorectal cancer

Frisbie Memorial Hospital is now using low-dose CT scanning as a follow-up tool for screening colorectal cancer. This procedure, known as virtual colonoscopy, does not replace the effective and most reliable colorectal cancer screening tool, which is the colonoscopy, but rather it is utilized as a means to obtain additional images of the colon and rectum. [More]
Duke Medicine scientists produce 3-D map of human brain stem using MRI technology

Duke Medicine scientists produce 3-D map of human brain stem using MRI technology

Scientists at Duke Medicine have produced a 3-D map of the human brain stem at an unprecedented level of detail using MRI technology. [More]
Wistar Institute scientists find new biomarker that appears to be more accurate at detecting NSCLC

Wistar Institute scientists find new biomarker that appears to be more accurate at detecting NSCLC

Survival rates for patients with lung cancer increase dramatically the earlier the disease is diagnosed, underscoring the need for effective biomarkers that can be used for detection. Now, scientists at The Wistar Institute have found a protein that circulates in the blood that appears to be more accurate at detecting non-small cell lung cancer (NSCLC) than currently available methods used for screening. [More]
Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory. [More]
Researchers examine neuroimaging findings in children with sports-related concussions

Researchers examine neuroimaging findings in children with sports-related concussions

Researchers from the Canada North Concussion Network in Manitoba examined neuroimaging studies obtained in children and adolescents with sports-related concussions and found that the images appeared normal in 78% of cases. [More]
Ultrasound becoming the most widely used imaging tool in medicine today

Ultrasound becoming the most widely used imaging tool in medicine today

Mention "ultrasound" and most people likely will think of an image of a fetus in a mother's womb. But while providing peeks at the not-yet-born is one of ultrasound's most common applications, that's only a small part of the picture. [More]
NCCN ORP and Pfizer IGLC collaborate to improve lives of people with metastatic breast cancer

NCCN ORP and Pfizer IGLC collaborate to improve lives of people with metastatic breast cancer

The National Comprehensive Cancer Network Oncology Research Program is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to establish a peer-reviewed grant program to elicit proposals focused on health care provider performance and/or health care quality improvement and education projects. [More]
Tools that help decide use of expensive imaging studies can reduce ordering of unnecessary tests

Tools that help decide use of expensive imaging studies can reduce ordering of unnecessary tests

Using tools that help physicians decide whether to use expensive imaging studies such as MRI scans can help reduce the ordering of unnecessary tests, but implementation of the tools in real-world settings has many challenges, according to a new RAND Corporation study. [More]
ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago. [More]
NCCN to host policy summit on emerging issues in tissue allocation

NCCN to host policy summit on emerging issues in tissue allocation

Tissue allocation is a growing issue of concern for many researchers due, in part, to expanding research interests in precision medicine. The increased demand by pharmaceutical and biotech companies for patient tissue specimens collected for clinical care and trials presents clinical, ethical, and legal issues. [More]
Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Advertisement
Advertisement